Sinopep-Allsino Biopharmaceutical's Plant Passes Regulatory Inspection

Jiangsu Sinopep-Allsino Biopharmaceutical's (SHA:688076) production line passed the good manufacturing practices or GMP inspection of the drug regulator of China's Jiangsu Province, according to the

MT NewswiresJul 11 05:52 ET

Nuocheng Bio (688076.SH): the new oral solid preparation workshop and hard capsule production line passed the pharmaceutical GMP compliance inspection.

Notech Biotechnology (688076.SH) announced that its 203 workshop at the China Medicine Port plant has been inspected for compliance with FDA/EM...

Zhitong FinanceJul 10 06:14 ET

The actual controller and its concerted parties of Neutai Bio (688076.SH) have cumulatively reduced their shareholding of 660,000 shares of "Neutai Convertible Bonds".

Noted on July 2, Gelonghui: Notable Bio (688076.SH) announced that it has recently received a notice from the controlling shareholder and actual controller. It was learned that the actual controllers Zhao Deyi and Zhao Dezhong and their concerted actions will reduce their holdings of 660,000 "Note Bond" instruments between July 1 and July 2, 2024 through the Shanghai Stock Exchange system, accounting for 15.21% of the total issuance of "Note Bond".

Gelonghui FinanceJul 2 05:16 ET

Notable Biology (688076.SH): Intends to use the raised funds of 31.9184 million yuan for the implementation of the active pharmaceutical ingredient product development project.

On June 26th, Gelunhui announced that Nova Bio (688076.SH) held its 20th meeting of the third board of directors and the 17th meeting of the third supervisor board on June 26th, 2024. They approved the proposal on using part of the raised funds to increase the capital of wholly-owned subsidiary for implementing the raised investment project. The company agreed to use 31,918,400 yuan of the raised funds to implement the "active pharmaceutical ingredient R&D project". The company will provide 31,918,400 yuan of raised funds to Hangzhou Nova Biomedical Technology Co., Ltd. ("Nova") by increasing its capital. After the capital increase is completed this time,

Gelonghui FinanceJun 26 06:18 ET

Investors Appear Satisfied With Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd.'s (SHSE:688076) Prospects As Shares Rocket 29%

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHSE:688076) shareholders have had their patience rewarded with a 29% share price jump in the last month. The last month tops off a massive incr

Simply Wall StJun 21 18:09 ET

Jiangsu Sinopep-Allsino Biopharmaceutical: Voluntary disclosure announcement of the 2024 semi-annual performance forecast.

Sensex a shareJun 19 12:00 ET · Announcements